Man Group PLC Rain Therapeutics Inc. Transaction History

Man Group PLC

  • $36 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$7.77 - $12.47 $21,981 - $35,277
-2,829 Reduced 17.4%
13,430 $117,000
Q4 2022

Feb 14, 2023
BUY
$5.52 - $8.48 $89,749 - $137,876
16,259 New
16,259 $130,000

Others Institutions Holding RAIN

# of Institutions
3
Shares Held
122K
Call Options Held
0
Put Options Held
0
View Full List

About Rain Therapeutics Inc.

RAIN Quotes by TradingView
  • Ticker RAIN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,837,400
  • Description
  • Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...
More about RAIN
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email